Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS (Leukemia (2014) 29 (1033-1040) DOI: 10.1038/leu.2013.305);Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Leukemia

Volumn 28, Issue 5, 2014, Pages 1033-1040

  List, A F ^a   Bennett, J M ^b   Sekeres, M A ^c   Skikne, B ^d   Fu, T ^d   Shammo, J M ^e   Nimer, S D ^f   Knight, R D ^d   Giagounidis, A ^g  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d CELGENE CORPORATION   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g MARIEN HOSPITAL DÜSSELDORF   (Germany)

Author keywords

acute myeloid leukemia; del(5q); lenalidomide; myelodysplastic syndromes; transfusion independence

Indexed keywords

HEMOGLOBIN; LENALIDOMIDE;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BONE MARROW BLAST COUNT; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MASCULINITY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; CHROMOSOME DELETION; DISEASE PROGRESSION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 84899912822     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.312     Document Type: Erratum

References (18)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
2. Nimer SD. Myelodysplastic syndromes. Blood 2008; 111: 4841-4851.
3. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N. et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008; 451: 335-339.
4. Giagounidis AA, Germing U, Haase S, Hildibrandt B, Schlegelberger B, Schoch C. et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004; 18: 113-119.
5. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstroöm- Lindberg E. The WHO classification does make a difference. Blood 2004; 103: 3265-3270.
6. Kelaidi C, Park S, Brechignac S, Mannone L, Vey N, Dombret H. et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 2008; 32: 1049-1053.
7. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of the long arm of no. 5 chromosome. Nature 1974; 251: 437-438.
8. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG. et al. WHO-defined ?myelodysplastic syndrome with isolated del(5q)? in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010; 24: 1283-1289.
9. Mallo M, Cervera J, Schanz J, Such E, Garaa-Manero G, Luño E. et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011; 25: 110-120.
10. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
11. List AF, Wride K, Dewald GW, Bennett JM, Giagounidis A, Kurtin S. et al. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion. Leuk Res 2007; 31(Suppl 1): S38 (abstract C028).
12. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765-3776.
13. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD. et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
14. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557.
15. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q. et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-12979.
16. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E. et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
17. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006; 91: 1588-1590.
18. Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Pfeilstöcker M. et al. Survival, prognostic factors, and rates of leukemic transformation in a multicenter study of 303 untreated patients with MDS and del(5q) [abstract]. Blood 2009; 114: Abstract 945.